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With great interest, we gratefully appreciated the evaluation
of an algorithm for life-threatening postpartum hemorrhage
by Dr. Goodnough and coworkers [1] in Transfusion recently.
However, the transfusion protocol presented neither is evi-
dence-based nor specifically goal-directed towards the lead-
ing pathomechanisms of postpartum hemorrhage (PPH) [2, 3].
Our criticism concerns the lacking evidence for the used cut-
off values employed in this transfusion protocol for INR,
platelet count, and fibrinogen. Fibrinogen levels might better
be maintained at a higher level above 200 mg/dl [4] as op-
posed to 100 mg/dl.
Furthermore, we recommend the use of thrombelastography
in addition to standard laboratory tests for two reasons: i)
There is a higher rate of hyperfibrinolyses in postpartal hem-
orrhage and only thrombelastography detects this coagulopa-
thy reliably. ii) The delay between blood sampling and test re-
sult information is essential for the choice of the right therapy.
We do not agree with the authors’ statement that availability
of ‘super-stat’ laboratory results (15–30 min) would be superi-
or to thrombelastography [1]. Even though faster than nor-
mally obtained, conventional ‘super-stat’ laboratory tests do
not allow reliable diagnosis of frequent causes evolving in
PPH in a dramatic pace – hyperfibrinolysis, dilution and con-
sumption of coagulation potential [2]. The listed conventional
laboratory tests analyze plasma coagulation to the point
where clotting starts, but they do not cover fibrin polymeriza-
tion, interaction with platelets, and fibrinolysis. Measurement
of D-dimers have a low test specifity for hyperfibrino-
lysis [5], whereas multi-channel rotational thrombelastometry
(ROTEM®) enables the valid differentiation of hyperfibrinol-
ysis from other influences such as dilution or colloid effects
[6, 7]. In addition, thrombelastometry is highly sensitive to fib-
rinogen deficiency [8]. Although regular ROTEM® results
usually are obtained after only 100 s (coagulation time CT),
160 s (clot formation time CFT) and 15 min (clot firmness
after 15 min [9], diagnosis of late hyperfibrinolysis may need
longer with this method (see also fig. 1). An algorithm based
on the solely use of routine laboratory results does not consid-
er the therapeutic option of antifibrinolytic drugs.
Finally, we agree with the authors that for the first minutes of
a life-threatening hemorrhage a rigid relationship of red blood
cells, plasma, and platelets may be a reasonable advice. How-
ever, the adherence to this ratio as designed in their transfu-
sion algorithm will result in an insufficient substitution of both
coagulation factors and fibrinogen (the clot substance). The
correction of a 60% loss of plasma in a 70 kg parturient during
ongoing bleeding aiming at a 80% concentration of coagula-
tion factors requires a volume of 40% × 70 kg = 2,800 ml,
equaling 8–10 units. Taking into account the higher average
body weight and increased plasma volume of parturients, the
needed plasma transfusion volume might increase further.
Early use of cryoprecipitate and, if available (as it is in Eu-
rope), purified fibrinogen concentrate is recommended to im-
prove efficacy and to avoid massive volume overload. Substi-
tution therapy optimally is guided by thrombelastography 
(alternative but minor are fibrinogen levels). Other options
are the early use of refrigerated or lyophilized plasma as well
as the limited use of synthetic colloids [10].
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Fig. 1. a Fulminant hyperfibrinolysis shows an immediate breakdown of
the clot within 30 min. b Intermediate hyperfibrinolysis with a breakdown
of the clot between 30–60 min. c Late hyperfibrinolysis: clot breakdown
after 60 min.
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